Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21-65
SponsorUniversity of California, San Francisco
About this trial
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
Eligibility criteria
Qualifiers
Heart rate < 105 beats per minute (BPM)*
Systolic Blood Pressure < 160 and > 90*
Diastolic Blood Pressure < 100 and > 50*
Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)
Disqualifiers
Heart disease
Seizures
Cancer
Thyroid disease (okay if controlled with medication)
Trial design
Treatments tested in this trial
- Cannabis
- Nicotine
- Pax Loose Leaf Vaporizer
- Placebo Marijuana
Treatment groups
48 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Sponsors and collaborators
University of California, San Francisco
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
National Institutes of Health (NIH)
Collaborator
Food and Drug Administration (FDA)
Collaborator
Source ClinicalTrials.gov